Literature DB >> 21251875

Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies.

Alex J Mitchell1, Melissa Chan, Henna Bhatti, Marie Halton, Luigi Grassi, Christoffer Johansen, Nicholas Meader.   

Abstract

BACKGROUND: Substantial uncertainty exists about prevalence of mood disorders in patients with cancer, including those in oncological, haematological, and palliative-care settings. We aimed to quantitatively summarise the prevalence of depression, anxiety, and adjustments disorders in these settings.
METHODS: We searched Medline, PsycINFO, Embase, and Web of Knowledge for studies that examined well-defined depression, anxiety, and adjustment disorder in adults with cancer in oncological, haematological, and palliative-care settings. We restricted studies to those using psychiatric interviews. Studies were reviewed in accordance with PRISMA guidelines and a proportion meta-analysis was done.
FINDINGS: We identified 24 studies with 4007 individuals across seven countries in palliative-care settings. Meta-analytical pooled prevalence of depression defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) criteria was 16·5% (95% CI 13·1-20·3), 14·3% (11·1-17·9) for DSM-defined major depression, and 9·6% (3·6-18·1) for DSM-defined minor depression. Prevalence of adjustment disorder alone was 15·4% (10·1-21·6) and of anxiety disorders 9·8% (6·8-13·2). Prevalence of all types of depression combined was of 24·6% (17·5-32·4), depression or adjustment disorder 24·7% (20·8-28·8), and all types of mood disorder 29·0% (10·1-52·9). We identified 70 studies with 10,071 individuals across 14 countries in oncological and haematological settings. Prevalence of depression by DSM or ICD criteria was 16·3% (13·4-19·5); for DSM-defined major depression it was 14·9% (12·2-17·7) and for DSM-defined minor depression 19·2% (9·1-31·9). Prevalence of adjustment disorder was 19·4% (14·5-24·8), anxiety 10·3% (5·1-17·0), and dysthymia 2·7% (1·7-4·0). Combination diagnoses were common; all types of depression occurred in 20·7% (12·9-29·8) of patients, depression or adjustment disorder in 31·6% (25·0-38·7), and any mood disorder in 38·2% (28·4-48·6). There were few consistent correlates of depression: there was no effect of age, sex, or clinical setting and inadequate data to examine cancer type and illness duration.
INTERPRETATION: Interview-defined depression and anxiety is less common in patients with cancer than previously thought, although some combination of mood disorders occurs in 30-40% of patients in hospital settings without a significant difference between palliative-care and non-palliative-care settings. Clinicians should remain vigilant for mood complications, not just depression. FUNDING: None.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21251875     DOI: 10.1016/S1470-2045(11)70002-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  517 in total

1.  Emotional adjustment over 1 year post-diagnosis in patients with cancer: understanding and predicting adjustment trajectories.

Authors:  W Linden; R MacKenzie; K Rnic; C Marshall; A Vodermaier
Journal:  Support Care Cancer       Date:  2014-11-01       Impact factor: 3.603

Review 2.  Psychosocial care in cancer.

Authors:  Samantha B Artherholt; Jesse R Fann
Journal:  Curr Psychiatry Rep       Date:  2012-02       Impact factor: 5.285

Review 3.  Sleep disturbance, inflammation and depression risk in cancer survivors.

Authors:  Michael R Irwin; Richard E Olmstead; Patricia A Ganz; Reina Haque
Journal:  Brain Behav Immun       Date:  2012-05-24       Impact factor: 7.217

4.  Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database.

Authors:  Cécile Conte; Manuela Rueter; Guy Laurent; Robert Bourrel; Maryse Lapeyre-Mestre; Fabien Despas
Journal:  Support Care Cancer       Date:  2016-07-19       Impact factor: 3.603

5.  Palliative Care Providers' Practices Surrounding Psychological Distress Screening and Treatment: A National Survey.

Authors:  Elissa Kozlov; Claude Eghan; Sheila Moran; Keela Herr; M Carrington Reid
Journal:  Am J Hosp Palliat Care       Date:  2017-12-06       Impact factor: 2.500

Review 6.  Psychosocial Issues in Patients with Head and Neck Cancer: an Updated Review with a Focus on Clinical Interventions.

Authors:  Joshua D Smith; Andrew G Shuman; Michelle B Riba
Journal:  Curr Psychiatry Rep       Date:  2017-09       Impact factor: 5.285

7.  The use of psychological supportive care services and psychotropic drugs in patients with early-stage breast cancer: a comparison between two institutions on two continents.

Authors:  Orit Kaidar-Person; Icro Meattini; Allison M Deal; Giulio Francolini; Giulio Carta; Lauren Terzo; Jayne Camporeale; Hyman Muss; Lawrence B Marks; Lorenzo Livi; Deborah K Mayer; Timothy M Zagar
Journal:  Med Oncol       Date:  2017-07-19       Impact factor: 3.064

8.  Clinic-based depression screening in lung cancer patients using the PHQ-2 and PHQ-9 depression questionnaires: a pilot study.

Authors:  J Michael Randall; Rochelle Voth; Erin Burnett; Lyudmila Bazhenova; Wayne A Bardwell
Journal:  Support Care Cancer       Date:  2013-01-17       Impact factor: 3.603

9.  New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy.

Authors:  Daniel C McFarland
Journal:  Gen Hosp Psychiatry       Date:  2019-04-18       Impact factor: 3.238

10.  IT-based Psychosocial Distress Screening in Patients with Sarcoma and Parental Caregivers via Disease-specific Online Social Media Communities.

Authors:  Florian Pohlig; Ulrich Lenze; Heinrich M L Muhlhofer; Florian W Lenze; Johannes Schauwecker; Carolin Knebel; Tanja Zimmermann; Peter Herschbach
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.